Cytokinetics: Funding, Investors & Team (Sep 2026)
Cytokinetics is a late-stage biopharmaceutical organization zeroed in on finding, creating and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as expected medicines for weakening illnesses in which muscle execution is compromised or potentially declining.
Cytokinetics has raised $1.0B across 2 funding rounds on record, the most recent an undisclosed round of $550M announced in May 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Cytokinetics Company Profile and Key Stats
Latest funding round on record: May 2024.
Cytokinetics Funding Rounds
Cytokinetics raised $450M in a Post-IPO Debt announced in Jul 2022.
1.8 years later, an undisclosed round of $550M was announced in May 2024.
Cytokinetics Founders and Leadership Team
Contact details for the Cytokinetics team: 1 of 2 have an email address on file.
Start 14-day free trial →Cytokinetics Funding Compared to Other Biotechnology Startups
Cytokinetics' latest round of $550M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Cytokinetics in Biotechnology and South San Francisco
Companies Similar to Cytokinetics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Cytokinetics Funding FAQs
What does Cytokinetics do?
Cytokinetics is a late-stage biopharmaceutical organization zeroed in on finding, creating and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as expected medicines for weakening illnesses in which muscle execution is compromised or potentially declining.
How much funding has Cytokinetics raised?
Cytokinetics has raised $1.0B across 2 rounds on record. The most recent is an undisclosed round of $550M announced in May 2024.
When did Cytokinetics last raise funding?
Cytokinetics' most recent funding round on record is an undisclosed round of $550M, announced in May 2024.
Who founded Cytokinetics?
FundedIQ lists James Sabry (Founder) at Cytokinetics.
Who is the CEO of Cytokinetics?
Robert Blum is listed as CEO at Cytokinetics.
Where is Cytokinetics headquartered?
Cytokinetics is based in South San Francisco, California, United States.
How many employees does Cytokinetics have?
Cytokinetics is in the 51-100 employee band.
How does Cytokinetics' funding compare to other Biotechnology startups?
Cytokinetics' latest round of $550M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Cytokinetics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Cytokinetics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.